6 reports

  • 9.2 Growing Incidence of Cancer Patients in South Korea
  • South Korea- Number of Patient Diagnosed With Cancer (Thousand), 2009 - 2016

Korea Proton Therapy Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast is a research study published by Renub Research. According to this research South Korea Proton Therapy Market is expected to almost triple by 2021 from its current market size in 2016. Untapped Proton Therapy Market for South Korea was...

  • Cancer
  • South Korea
  • Demand
  • Market Size
  • Varian Medical Systems, Inc.
  • 7.2 Growing Incidence of Cancer Patients
  • SOUTH KOREA - NUMBER OF PATIENT DIAGNOSED WITH CANCER (NUMBER), 2007 - 2016

South Korea proton therapy market is anticipated to almost three-fold during the period 2016 - 2022. The number of patients treated with Proton Therapy in South Korea is very low whereas; the potential candidates for proton therapy are huge. Unfortunately, the access to proton therapy is limited for a vast population, owing to...

  • Cancer
  • Diagnostic Imaging
  • South Korea
  • Forecast
  • Market Size

South Korea Cancer Demographics ##. ## Incidence by Site ##.

  • Cancer
  • Pathology
  • South Korea
  • Forecast
  • Green Cross Cell Corp - Opportunities
  • Name

Senior citizens already contribute a great deal to the sales of drugs for most of the age related cancers such as breast cancer, prostate cancer, lung cancer, colorectal cancer, non-Hodgkin' s lymphoma, melanoma, and brain cancer.

  • Cancer
  • Pharmaceutical
  • South Korea
  • World
  • Company Financials
  • SILLAJEN ENTERS INTO R&D AGREEMENT WITH NATIONAL CANCER INSTITUTE
  • REGENERON PHARMA AND SILLAJEN BIOTHERAPEUTICS ENTER INTO AGREEMENT

Summary Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer.The company’s pipeline product includes Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment...

  • Biotherapeutic
  • Cancer
  • South Korea
  • M&A
  • BioTherapeutics Inc.
  • DEBT OFFERING
  • PARTNERSHIPS

The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient.

  • Cancer
  • South Korea
  • Company
  • Deals & Alliance
  • Green Cross